載入...
First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile
Tyrosine kinase inhibitors are de facto the more used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). Among these, sunitinib and pazopanib have reported greater activity in term of progression-free survival and overall survival compared with interferon-α or placeb...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Landes Bioscience
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3938518/ https://ncbi.nlm.nih.gov/pubmed/24253418 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.27150 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|